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 Thrombotic Event (n = 3) 3.2%
 Any Bleeding Event (n = 6) 6.25%
  No Thrombotic or Bleeding Event  
(n = 87) 90.6%
 Changes in eGFR (n = 8) 57.1%
  New Onset Thrombosis (n = 3)  
21.4%
 Any Bleeding Event (n = 3) 21.4%
 Major Bleeding Events (n = 1) 16.6%
  Non-Major Clinically Relevant Bleeding 
Events (n = 5) 83.3%
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Background
•  Patients positive for COVID-19 have been observed to be at a higher risk for venous 
thromboembolism (VTE) due to theorized endothelial damage secondary to the infection.
•  Factoring in prolonged hospital stays and other high-risk patient comorbidities with 
endothelial damage from hypoxic respiratory failure puts these patients at an enhanced 
probability of a hypercoagulable state. This confluence of events potentially leading to 
thromboembolic events.
•  At the Lehigh Valley Health Network, enoxaparin 0.5 mg/kg q12h was utilized as part of 
an anticoagulation protocol. It was approved for use in select COVID-19 positive patients 
as VTE prophylaxis in the absence of bleeding contraindications, confirmed/known VTE, 
or continuous renal replacement therapy (CRRT).
•  The observations from this study will help healthcare professionals treating patients with 
COVID-19 better understand the range of clinical outcomes that were associated with 
intermediate dosing anticoagulation with enoxaparin in this population.
Purpose
The purpose of this medication use evaluation is to assess the observed outcomes 
associated with the utilization of enoxaparin hybrid dosing in select COVID-19 positive 
patients for VTE prophylaxis.
Methods
STUDY DESIGN
•  This was a retrospective chart review that was performed at Lehigh Valley Hospital–
Cedar Crest (LVH–Cedar Crest) in Allentown, Pa., assessing the clinical impacts of a 
protocol directed hybrid dose of enoxaparin in select COVID-19 positive patients treated 
from April 1, 2020 to June 30, 2020.
•  Selected data was collected from patients who received enoxaparin 0.5 mg/kg 
subcutaneous q12h for VTE prophylaxis
   Patients included in the analysis: 
    Patients with a documented positive COVID-19 test during treatment
    At least one dose of (enoxaparin 0.5 mg/kg subcutaneous q12h) was administered 
during admission
   Patients excluded from the design:
    < 18 years old
    Treated in the outpatient setting
•  Counts and percentages were calculated using Microsoft Excel™
PRIMARY ENDPOINT
•  Identify the incidence of new onset of thrombosis or bleeding in COVID-19 patients  
within 24 hours after receiving a hybrid dose of enoxaparin 0.5 mg/kg q12h for VTE 
prophylaxis at LVH–Cedar Crest between April 1, 2020 to June 30, 2020.
SECONDARY ENDPOINTS
•  Identify COVID-19 patients who initially received enoxaparin 0.5 mg/kg q12h for VTE 
prophylaxis but then required a dose adjustment due to changes in eGFR, a new onset  
of thrombosis, or bleeding at LVH–Cedar Crest between April 1, 2020 to June 30, 2020.
•  Calculate the percentage of COVID-19 patients who experienced a major bleeding  
event vs non-major bleeding event who received enoxaparin 0.5 mg/kg q12h for VTE 
prophylaxis within 24 hours of the event at LVH–Cedar Crest between April 1, 2020 to 
June 30, 2020.
Results
A total of 96 patients were included in this analysis.
TABLE 1: PATIENT DEMOGRAPHICS
Mean Age (years) 63.7
Gender – Males, n (%) 38 (39.6%)
ICU patients, n (%) 68 (70.8%)
Mean weight (kg) 84.4
>120 kg, n (%) 6 (6.25%)
90-120 kg, n (%) 30 (31.3%)
60-90 kg, n (%) 53 (55.2%)
<60 kg, n (%) 7 (7.3%)
TABLE 2: AVERAGE MAXIMUM AND MINIMUM LAB VALUES WHILE RECEIVING ENOXAPARIN 
HYBRID DOSE
Average Maximum Values Average Minimum Values
Hemoglobin (g/dL) 12.0 10.0
Platelets (thou/cmm) 373 226
eGFR (mL/min/1.73 m2) 89.8 66.7
D-dimer (µ/mL) 4.05 2.01
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Conclusion
•  The most common demographics in this study were older adults (mean = 64 
years old), women (n = 58), and patients located within an ICU setting (n = 68).
•  The most common reason recorded for adjustments made to therapy was a 
sudden change in eGFR (8 of 14) that prompted the use a different dose or an 
alternative anticoagulant.
•  Out of the total number of bleeding events that occurred after receiving enoxaparin 
hybrid dosing, 1 was considered a major bleed while 5 were considered clinically-
relevant non-major bleeds.
   This major bleeding event contributed to a drop in hemoglobin >2 g/dL but did 
not lead to a fatal outcome.
    Risk factors for bleeding in patients on VTE prophylaxis present in this patient 
included older age (79 years old), female, hypertension, and renal insufficiency.
•  Only two of the five non-major clinically relevant bleeding events prompted a dose 
adjustment.
   Events that lead to increased level of care or documentation include recurrent 
epistasis, tracheal, mucosal, arterial line, and GI bleeding.
   Risk factors for bleeding in patients on VTE prophylaxis present in these patients 
include three female patients, three patients of older age, four with hypertension, 
and three with renal insufficiency.
•  A total of three thrombotic events occurred that prompted a dosage increase to full 
anticoagulation from enoxaparin (1 mg/kg q12h subcutaneous) due to two 
occlusive thrombi and one superficial vein thrombosis.
   Risk factors for thrombosis in patients on VTE prophylaxis in these patients 
include three patients >40 years old, three patients on bed rest ≥5 days, and 2 
obese patients.
•  The results of this MUE provide us with a better understanding of bleeding and 
thrombotic event incidence rates in COVID-19 patients receiving a hybrid dose of 
enoxaparin not typically used in other patient populations. 
   Although a small patient population was analyzed in this study, this information 
will contribute to current literature in regards on how to manage patients with 
this novel coronavirus. 
   The bleeding and thrombosis rates found in this MUE are comparable to what 
was found in a larger trial conducted in the United States in a similar patient 
population.
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